ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

od Sullivan, Ivana, Planchard, David
izdano v Ther Adv Med Oncol (2016)

Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial”

od Sullivan, Ivana, Planchard, David
izdano v J Thorac Dis (2016)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line

od Sullivan, Ivana, Planchard, David
izdano v Front Med (Lausanne) (2017)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer

od Mezquita, Laura, Planchard, David
izdano v Cancer Manag Res (2018)

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

od Sullivan, Ivana, Planchard, David
izdano v Ther Adv Respir Dis (2016)

Oncogene addiction and immune escape: friends or foes?

od Abdayem, Pamela, Planchard, David
izdano v Ann Transl Med (2020)

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression

od Abdayem, Pamela, Planchard, David
izdano v Transl Lung Cancer Res (2020)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

od Botticella, Angela, Mezquita, Laura, Le Pechoux, Cecile, Planchard, David
izdano v Ther Adv Respir Dis (2019)

Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report

od Niu, Xiaomin, Sun, Yingjia, Planchard, David, Chiu, Luting, Bai, Jian, Ai, Xinghao, Lu, Shun
izdano v Front Oncol (2021)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

od Facchinetti, Francesco, Levy, Antonin, Ammari, Samy, Naltet, Charles, Lavaud, Pernelle, Aldea, Mihaela, Vasseur, Damien, Planchard, David, Besse, Benjamin
izdano v Cancer Manag Res (2021)

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

od Schernberg, Antoine, Mezquita, Laura, Boros, Angela, Botticella, Angela, Caramella, Caroline, Besse, Benjamin, Escande, Alexandre, Planchard, David, Le Péchoux, Cécile, Deutsch, Eric
izdano v PLoS One (2018)

Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment

od Antoun, Sami, Morel, Hugues, Souquet, Pierre‐Jean, Surmont, Veerle, Planchard, David, Bonnetain, Franck, Foucher, Pascal, Egenod, Thomas, Krakowski, Ivan, Gaudin, Hélène, Debieuvre, Didier
izdano v J Cachexia Sarcopenia Muscle (2019)

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

od Passaro, Antonio, Addeo, Alfredo, Von Garnier, Christophe, Blackhall, Fiona, Planchard, David, Felip, Enriqueta, Dziadziuszko, Rafal, de Marinis, Filippo, Reck, Martin, Bouchaab, Hasna, Peters, Solange
izdano v ESMO Open (2020)

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer

od Kas, Baptiste, Talbot, Hugues, Ferrara, Roberto, Richard, Colombe, Lamarque, Jean-Philippe, Pitre-Champagnat, Stéphanie, Planchard, David, Balleyguier, Corinne, Besse, Benjamin, Mezquita, Laura, Lassau, Nathalie, Caramella, Caroline
izdano v JAMA Oncol (2020)

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients

od Boros, Angela, Lacroix, Ludovic, Lacas, Benjamin, Adam, Julien, Pignon, Jean-Pierre, Caramella, Caroline, Planchard, David, de Montpreville, Vincent, Deutsch, Eric, Levy, Antonin, Besse, Benjamin, Pechoux, Cécile Le
izdano v Oncotarget (2017)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

od Oulhen, Marianne, Pawlikowska, Patrycja, Tayoun, Tala, Garonzi, Marianna, Buson, Genny, Forcato, Claudio, Manaresi, Nicolò, Aberlenc, Agathe, Mezquita, Laura, Lecluse, Yann, Lavaud, Pernelle, Naltet, Charles, Planchard, David, Besse, Benjamin, Farace, Françoise
izdano v NPJ Precis Oncol (2021)

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

od Yamamoto, Nobuyuki, Hayashi, Hidetoshi, Planchard, David, Morán, Teresa, Gregorc, Vanesa, Dowell, Jonathan, Sakai, Hiroshi, Yoh, Kiyotaka, Nishio, Makoto, Cortot, Alexis B., Benhadji, Karim A., Soni, Nital, Huang, Jinhong, Makris, Lukas, Cedres, Susana
izdano v Invest New Drugs (2020)

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

od Park, Wungki, Mezquita, Laura, Okabe, Naoyuki, Chae, Young Kwang, Kwon, Deukwoo, Saravia, Diana, Auclin, Edouard, Planchard, David, Caramella, Caroline, Ferrara, Roberto, Agte, Sarita, Oh, Michael, Mudad, Raja, Jahanzeb, Mohammad, Suzuki, Hiroyuki, Besse, Benjamin, Lopes, Gilberto
izdano v Br J Cancer (2019)

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

od Remon, Jordi, Swalduz, Aurelie, Planchard, David, Ortiz-Cuaran, Sandra, Mezquita, Laura, Lacroix, Ludovic, Jovelet, Cecile, Rouleau, Etienne, Leonce, Camille, De Kievit, Frank, Morris, Clive, Jones, Greg, Mercier, Kelly, Howarth, Karen, Green, Emma, Pérol, Maurice, Saintigny, Pierre, Besse, Benjamin
izdano v PLoS One (2020)

An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

od Planchard, David, Besse, Benjamin, Groen, Harry J M, Souquet, Pierre-Jean, Quoix, Elisabeth, Baik, Christina S, Barlesi, Fabrice, Kim, Tae Min, Mazieres, Julien, Novello, Silvia, Rigas, James R, Upalawanna, Allison, D’Amelio, Anthony M, Zhang, Pingkuan, Mookerjee, Bijoyesh, Johnson, Bruce E
izdano v Lancet Oncol (2016)